Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). Patients and Methods: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%−37%]. Median duration of response (DOR) was 4.2 months (range: 1.0+−9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%−43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%−35%), median DOR of 6.0 months (range: 1.0+−9.7), and 6-month PFS rate of 40% (95% CI: 24%−55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30859-3 · Cited by 237
Self-citation
Cited by
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00056-5 · Cited by 410
Self-citationNCCN Guidelines® Insights: Cervical Cancer, Version 1.2024: Featured Updates to the NCCN Guidelines
Abu-Rustum, N. R., Yashar, C. M., Arend, R., Barber, E., Bradley, K., Brooks, R., Campos, S. M., Chino, J., Chon, H. S., Crispens, M. A., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0062 · Cited by 384
Karthikeyan, A., Joseph, A., & Nair, B. G. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00290-4 · Cited by 336
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
Metadata
- Authors
- Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H.-T., Machiels, J.-P., Spicer, J. F., Jones, R., Forster, M. D., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., Lassen, U. N., & Coleman, R. L.
- Venue
- Clinical Cancer Research
- Published
- 2020-03-13
- Volume
- 26
- Issue
- 6
- Pages
- 1220-1228
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2994242812
- Cited by
- 135
- References
- 1
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-2962
- The paper
- Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H.-T., Machiels, J.-P., Spicer, J. F., Jones, R., Forster, M. D., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., . . . Coleman, R. L. (2020). Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-2962
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.